Pharmacokinetics of a single evening dose of slow release theophylline in patients with chronic lung disease [letter]

Thompson, PJ; Butcher, MA; Frazer, LA; Marlin, G. E.

doi:10.1111/j.1365-2125.1981.tb01248.x

Cited by 21 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plasma concentration-time profile on the final 24 h was also remarkably similar to that observed by Scott et al (1980) in 13 asthmatic children, using the same sustained-release preparation. Thus, in general it would appear that the peak concentration during the night-time dosing interval occurs after 6 and 8 h: in one study with another sustained-release preparation, it was as long as 10 h (Thompson et al, 1981). In contrast, Kelly & Murphy (1980) whilst noting that the pre-dose concentration was higher at 08.00 than 20.00 h in 20 asthmatic children, found no other significant diurnal differences and concluded that substantial circadian variation did not occur during chronic administration.…”

Section: Resultsmentioning

confidence: 99%

Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained‐release preparation in patients with obstructive airways disease.

Taylor¹,

Duffin²,

Kinney³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

Circadian variation in plasma theophylline concentrations was studied in eight patients with obstructive airways disease during regular 12‐ hourly dosing at 09.00 and 21.00 h with a sustained‐release theophylline formulation. After regular dosing for a minimum period of 3 days, plasma concentration measurements were made at 09.00, 13.00, 21.00 and 01.00 h on 3 consecutive days and at more regular intervals during a complete 24 h period on day 4. On each day, theophylline concentrations for the first 4 h of the dosing interval were consistently higher during the day than at night. However, the differences were significant only at 13.00/01.00 h on day 2, and for each of the first 4 h on day 4. On day 4, following the dose at 21.00 h the mean peak plasma theophylline concentration occurred 6.9 +/‐ 0.8 h after dosing; in contrast, after the morning dose the mean peak concentration occurred at 4.5 +/‐ 0.8 h. However, the mean 'steady‐ state' concentrations during the two dose intervals were not significantly different. Thus circadian variations in plasma drug concentrations do occur in patients taking maintenance theophylline therapy: differing rates of absorption may account for the observed pattern.

show abstract

Section: Resultsmentioning

confidence: 99%

Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained‐release preparation in patients with obstructive airways disease.

Taylor¹,

Duffin²,

Kinney³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In the present study the time between dosing and peak plasma concentrations after regular treatment with this slow-release preparation was three times as long after the evening than after the morning dose, a difference which was not apparent during the first day of the study ( Figure 2a). Other authors have demonstrated a similar phenomenon in subjects who had not previously been fasted prior to receiving the evening dose (Scott et al, 1981;Thompson et al, 1981;Taylor et al, 1984). Pederson & Moeller-Peterson (1982) have observed that after a large meal at night a slow-release preparation of theophylline undergoes delayed absorption.…”

Section: Discussionmentioning

confidence: 73%

“…It is now widely accepted that slow-release pre-at night (Taylor et al, 1984;Lesko et al, 1980; parations of methylxanthines offer patients with Scott et al, 1981;Thompson et al, 1981). Thus, asthma some protection against nocturnal and in patients taking a conventional regime of two early morning symptoms.…”

Section: Introductionmentioning

confidence: 99%

Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma.

Hibberd¹,

Alveyn²,

Coombes³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

The day and night pharmacokinetics of assymetrical doses of slow release choline theophyllinate (Sabidal SR 270) were compared at day 1 and at day 4 of treatment when steady state had been achieved. Ten patients with chronic asthma were given oral choline theophyllinate 424 mg at 09.00 h and 848 mg at 21.00 h for 4 days. At regular intervals during day 1 and day 4 of treatment theophylline concentrations were measured in plasma and dried blood spots by fluorimmunoassay. Theophylline concentrations measured from dried blood spots were slightly lower than those in plasma, the difference remaining constant at all time points during day 1 and day 4 of treatment. On day 1 the mean peak plasma theophylline concentration was 5.4 +/‐ 1.0 (+/‐ s.e. mean) micrograms ml‐1 4 h after the morning dose and 11.2 +/‐ 1.6 micrograms ml‐1 4 h after the evening dose which were significantly (P less than 0.01) different. Similarly the areas under the plasma theophylline concentration‐time curves at night were significantly (P less than 0.001) greater than those observed during the day. During day 4 mean peak plasma concentrations of theophylline after the morning and larger evening dose were 13.2 +/‐ 1.3 and 12.1 +/‐ 1.4 micrograms ml‐1 respectively, which were not significantly different. No significant difference was observed between the areas under the plasma theophylline concentration‐time curves during the day and at night. However the post‐ dose time to peak was significantly delayed at night (6 h) compared to the morning (2 h, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…Patients are usually hospitalised in-patients [14][15][16], and both the patients or volunteers selected, as well as the conditions of the study, are careful ly controlled. For example, diet is often restricted to avoid xanthine-containing food and drinks on blood sampling days, patients are rested in hospital wards or in out-patient clinics rather than being ac tive, smoking is controlled or selected groups of smokers/non-smokers only are used [17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Sustained-Release Theophylline Preparations

Steenhoek¹,

Palmen

1984

Respiration

View full text Add to dashboard Cite

The comparative efficacy and patient compliance with treatment using three sustained-release theophylline preparations currently available in The Netherlands were evaluated by measuring the plasma concentration achieved in a survey of 282 hospital and 185 out-patients. Compliance was dramatically better amongst in-patients than those attending out-patient clinics. Complete treatment avoidance was higher than expected. Compliance was better among non-smokers than among patients who were still smoking. Patients clearly preferred preparations which permitted a simple daily dosing schedule requiring the minimum number of tablets. On this basis and that of the parameters measured, Theolair Retard was the preparation of choice. Plasma concentration should be monitored during long-term theophylline treatment.

show abstract

Pharmacokinetics of a single evening dose of slow release theophylline in patients with chronic lung disease [letter]

Cited by 21 publications

References 11 publications

Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained‐release preparation in patients with obstructive airways disease.

Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained‐release preparation in patients with obstructive airways disease.

Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma.

Sustained-Release Theophylline Preparations

Contact Info

Product

Resources

About